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Abstract
Background: Highly pathogenic avian influenza viruses are a serious threat to domestic poultry and can be a source
of new human pandemic and annual influenza strains. Vaccination is the main strategy of protection against influenza,
thus new generation vaccines, including DNA vaccines, are needed. One promising approach for enhancing the
immunogenicity of a DNA vaccine is to maximize its expression in the immunized host.
Methods: The immunogenicity of three variants of a DNA vaccine encoding hemagglutinin (HA) from the avian
influenza virus A/swan/Poland/305-135V08/2006 (H5N1) was compared in two animal models, mice (BALB/c) and
chickens (broilers and layers). One variant encoded the wild type HA while the other two encoded HA without
proteolytic site between HA1 and HA2 subunits and differed in usage of synonymous codons. One of them was
enriched for codons preferentially used in chicken genes, while in the other modified variant the third position of
codons was occupied in almost 100 % by G or C nucleotides.
Results: The variant of the DNA vaccine containing almost 100 % of the GC content in the third position of codons
stimulated strongest immune response in two animal models, mice and chickens. These results indicate that such
modification can improve not only gene expression but also immunogenicity of DNA vaccine.
Conclusion: Enhancement of the GC content in the third position of the codon might be a good strategy for
development of a variant of a DNA vaccine against influenza that could be highly effective in distant hosts, such
as birds and mammals, including humans.
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Background
Vaccines against influenza are traditionally produced
from viruses propagated in chicken embryos, however
the first formulations with antigens produced in cell lines
are also available, for example Flucelvax®. The traditional
techniques have a number of disadvantages: (i) the process
is slow and inflexible, which hinders a fast reaction in the
case of new outbreaks, (ii) capacity is too small to produce
enough doses, (iii) workers are exposed to the dangerous
live pathogen and (iv) the virus can mutate during propa-
gation. Moreover, highly pathogenic strains are difficult to
propagate in eggs in sufficient amounts, due to their
harmful effect on the host, and have to be reassorted or
genetically engineered. Problematic are also traces of
chicken proteins present in formulation, which are com-
mon allergens [1, 2]. The DNA vaccines seem to be a very
promising alternative with multiple advantages. They are
relatively easy and economical in production due to the
lack of long-lasting and complicated procedures of antigen
multiplication and purification. They can be quickly re-
designed and re-constructed in case of sudden new
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disease outbreaks. They guarantee antigens with native
structure, identical with those within infection, contain-
ing all posttranslational modifications, since they are
produced in vivo in host cells. Moreover, they are safe
and no infective form of the pathogen is needed at any
step. DNA itself is also more stable in storage and
transport than proteins. DNA vaccines induce both
humoral and cellular immunological responses, stimu-
lating T cells, antigen presenting cells and antibodies
production, ensure broad, long lasting and protective
response [3, 4]. Thus, it is not surprising that several
clinical trials of DNA vaccines against influenza are
now ongoing (http://clinicaltrials.gov/) [5, 6].
The expression level of cDNA encoding an antigen in
the cells of immunized host is an important factor influ-
encing the immunological potential of DNA-based vac-
cines. Manipulations within the coding sequence, such
as replacing the rare codons with the synonymous co-
dons preferred by the host organism and avoidance of
RNA secondary structures motifs or others unprofitable
features have been applied to improve the effectiveness
of DNA vaccines against influenza [7]. For example,
codon optimization of DNA vaccine based on HAs from
A/New Caledonia/20/99 (H1N1) and A/Panama/2007/99
(H3N2) not only enhanced its immunogenicity but also
might lead to the reduction of the number of required
doses [8]. Similar results were also reported for DNA vac-
cine based on HA derived from the swine influenza virus
A/Texas/05/2009 (H1N1) [9]. These authors demon-
strated that optimization of the codon bias of HA from
H1N1 resulted in stimulation of CD8+ (determined by
the high levels of TNF, IFNγ and IL-2) and in elevated
level of antibody production. Recently, also immunization
of ponies (mixed breeds of Shetland blood, Welsh blood,
Florida swamp pony blood) with monovalent or trivalent
DNA vaccines (with mammalian preferred codons) encod-
ing HAs from different strains of H3N8 equine influenza
was reported [10]. The vaccine was administered to ponies
that were subsequently challenged with the homologues
virus. The degree of protection, virus shedding and clinical
symptoms after infection were significantly reduced in
all immunized groups compared to the negative control.
Moreover, a moderate level of cross response was ob-
tained in the group that received the trivalent formulation.
Avian influenza is a serious and highly infectious dis-
ease of poultry and other bird species, caused by influ-
enza viruses which can be also transmitted to humans
causing high mortality [11, 12]. Therefore, development
of effective vaccines against avian influenza is very im-
portant. In birds, higher effectiveness of the DNA vac-
cine based on the HA variant with codons optimized for
chicken usage, where the optimized gene shared about
75 % nucleotides with the wild type gene, has been re-
ported by several independent research groups. The
examples include chicken [13] and Japanese quails [14]
immunization by different variants of H5 HA. The au-
thors mentioned several possible reasons of the observed
superiority of the modified plasmid, such as increased
expression due to usage of the chicken optimized codons,
increased mRNA stability due to increased GC content
and increased level of CpG motifs that could act as an ad-
juvant of immunological responses [13]. In contrast, no
significant seroconversion differences between the groups
immunized with the optimized and non-optimized vari-
ants were observed in the case of the DNA vaccine based
on HA from the low pathogenic H6N2 virus [15]. The au-
thors observed high inter-individual variation, possibly
due to poor efficiency of the delivery method and/or the
huge biological variation of individual responses. The H5
HA variants optimized for human preferred codons were
also tested. For example, a large set of different HA opti-
mized for human preferred codons was tested in mice and
chickens and proven to elicit robust protective immune
responses against a broad range of H5 influenza strains
[16]. Animals received several multivalent combinations
of DNA vaccines. Responses were tested by HI and virus
microneutralization tests with homologous and heterol-
ogous antigens, as well as by the challenge experiment.
The obtained results indicated protection against heterol-
ogous strains of highly pathogenic avian influenza H5N1
after vaccination with two doses of DNA vaccine. Another
interesting approach was applied by the researchers who
used the consensus sequence of H5 HA based on the
sequences from 467 different H5 strains, optimized it for
mammalian expression (using human preferred codons)
and observed not only its high expression level but also
strong protective immune response in vaccinated labora-
tory animals [17].
Most above-mentioned studies confirmed that codon
optimization to the codon bias of the host improves the
efficacy of DNA vaccine. However, several studies in
mammalian cells suggest that increasing the GC content
provides better mRNA stability, processing and nucleo-
cytoplasmic transport [18–21]. Because the distribution
of GC content among genes is similar in mammals and
birds (Additional file 1: Figure S1), we hypothesized that
GC content optimization might also lead to improved
expression and immunogenicity in birds. The DNA vac-
cine prepared according to such criterion could be effect-
ive in many types of hosts, its design would be simplified
and the obtained effects more universal. Therefore, the
goal of this study was to evaluate the immunogenicity of
the variant of DNA vaccine containing nearly 100 % of
codons with GC at the third position in two model ani-
mals, mice and chickens, and comparing it to the other
vaccine variants. All tested vaccine variants were based
on HA from the highly pathogenic avian influenza virus
A/swan/Poland/305-135V08/2006 (H5N1).
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Methods
Plasmids used for DNA vaccination
The HAw/pCI, K3/pCI and GK/pCI plasmids were used
for DNA vaccination. The HAw/pCI plasmid contains
the nucleotide sequence identical to the region encoding
the full-length HA from A/swan/Poland/305-135V08/
2006 (H5N1). The K3/pCI and GK/pCI plasmids contain
two different nucleotide sequences encoding the same H5
HA protein as HAw/pCI (with the leader peptide) but
without the proteolytic cleavage site (341-RRRKKRR-347)
between HA1 and HA2 subunits. The sequence encoding
HA, present in K3/pCI, was optimized for domestic
chicken (Gallus gallus) and the codon adaptation index
(CAI) reached 0.91. In contrast, the sequence encoding
HA, present in GK/pCI was not optimized to any codon
bias but it was was modified by changing the nucleotides
present in the third positions of the codons to either guan-
ine (G) or cytosine (C). The cDNA of K3 and GK were
synthesized by GeneScript (USA; http://www.genscript.
com/). Comparison of the HA sequences is shown in
Additional file 2: Figure S2. The inserts were cloned
into MluI and SalI restriction sites of the pCI expres-
sion vector (Promega, Wisconsin, USA) downstream of
the cytomegalovirus (CMV) promoter and upstream of
the SV40 late polyadenylation signal. Plasmids were
propagated in DH5α strain of Escherichia coli and
isolated using NucleoBond® PC 10000 EF Giga-scale
purification kit (Macherey-Nagel, Düren, Germany).
Transfection of mammalian cells
The mouse myoblast cells (2x105 cells; C2C12 line) were
transfected with 2 μg of HAw/pCI, K3/pCI, GK/pCI or
pCI using Lipofectamine® 3000 Reagent (ThermoFisher
Scientific, Waltham, USA) as described by the manufac-
turer. After 48h the cells were scraped off into the RIPA
buffer (ThermoFisher Scientific, Waltham, USA), trans-
ferred to the 1.5 ml tubes and frozen in liquid nitrogen,
following thawing at 37 °C (three times). The homoge-
nates were centrifuged at 10 000× g for 8 min at 4 °C
and the equal amounts of protein extract were analyzed
by SDS-PAGE (Nu-Page™ 4-12 % Bis-Tris gel, Invitrogen™,
Basel, Switzerland) and Western blotting. The nitrocellu-
lose membranes were blocked in 5 % milk in 1× TBS
buffer (50 mM Tris, pH 8, 150 mM NaCl, 1 % Tween 80)
and incubated for 1.5h with primary antibody anti – HA
(H5) (1:500, ImmuneTechnology, USA), or anti- GAPDH
(1:20000, Sigma, St. Louis, USA) and for 1h with second-
ary antibody (anti-rabbit or anti-mouse IgG (whole
molecule) − alkaline phosphatase antibody; Sigma, St.
Louise, USA). The enzymatic color reaction was generated
using NBT/BCIP Stock Solution (Roche, Switzerland).
The bands intensity was compared using the Image J
(https://imagej.nih.gov/ij/).
Immunization of animals
Vaccine doses were prepared by mixing plasmid DNA
(suspended in PBS, pH 7.4) with Lipofectin® (Invitrogen™,
Basel, Switzerland) in ratio 6:1 as described earlier [22].
Our previous results indicated that the DNA vaccination
was more effective when plasmid was used with a lipid
carrier (Additional file 3: Figure S3 and [22]). Schemes of
the immunization experiments are presented in Fig. 1 and
the number of animals and DNA doses used in each ex-
periment is indicated in Table 1. Specific-pathogen free
BALB/c female mice (5–6 weeks of age) were main-
tained in standard conditions with free access to water
and standard mouse diet at the experimental facility in
Mossakowski Medical Research Centre Polish Academy
of Sciences. Mice were immunized intramuscularly (in
quadriceps of left thigh; one spot) and obtained two 50-μl
doses of the vaccine, on days 35 and 49 (days of life). Sev-
eral doses of plasmid DNA were tested in order to choose
the most convenient dose for the comparison of the
vaccine variants. The blood samples were collected
three-fold: two weeks after the first immunization (day
49), one week (day 56) and two weeks (day 63) after the
second immunization. Broiler chickens (Ross 308) and
layer chickens (Rosa 1) were purchased from commer-
cial brooder on the hatching day and maintained in
standard bedding conditions at experimental poultry
house. Birds were immunized intramuscularly (in breast
muscle, one spot) on days 7 and 21 (day of life) using
60 μg of plasmid DNA mixed with Lipofectin® in a final
volume of 100 μl. The dose was chosen as optimal for
the purposes of this study based on our previous ex-
periment with chickens immunization [22, 23]. The
blood samples were collected from the wing vein on
days 21, 28 and 35 in Experiment 1 and on days 21 and
35 in Experiment 2.
All applicable international, national, and/or institutional
guidelines for the care and use of animals were followed.
The experiments of mice immunization were approved by
the Fourth Local Ethical Committee for Animal Experi-
ments at the National Medicines Institutes, Permit
Number 03/2014. The experiments with chickens were
approved by the Second Local Ethical Committee for
Animal Experiments at the Medical University of
Warsaw, Permit Number 17/2009.
Elisa
Mice: 96-well flat-bottom plates (MaxiSorp Surface, Nunc,
UK) were coated with 300 ng of purified recombinant H5
HA (A/swan/Poland/305-135V08/2006, H5N1) (derived
from a baculovirus system (Oxford Expression Technolo-
gies, UK) at 2–8 °C overnight. After removing the coating
buffer, the plates were washed three times with 1× PBST
(phosphate buffered saline with 0,05 % of Tween-20) and
blocked with 2 % of BSA-PBST at 37 °C for 90 min. After
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2 washes, the 100-fold in Experiment 1, Experiment 3 and
Experiment 4 and the 50-fold (49d) or 200-fold (56d and
63d) in Experiment 2 diluted sera samples were added
and incubated at 2–8 °C overnight. Next day, after 4
washes, plates was incubated for 1h at 37 °C with alkaline
phosphatase-conjugated goat anti-mouse IgG (Sigma
Aldrich, St. Louise, USA). The enzymatic color reaction
was performed using alkaline phosphatase yellow (pNPP)
liquid substrate (Sigma, St.LouiseUSA), stopped with 3M
NaOH and measured (OD405) using a Synergy/HT micro-
plate reader (BioTek Instruments, Inc.).
Chickens: 96-well flat-bottom plates (MediSorp Surface,
Nunc, UK) were coated with the same antigen as above.
After removing the coating buffer, the plates were washed
four times with 1× PBST and blocked with 2 % of BSA-
PBST at 37 °C for 90 min. Following 2 washes, the
200-fold diluted sera samples were added and incu-
bated at 2–8 °C overnight. Next day, after 5 washes
plates were incubated for 1h at 37 °C with peroxidase-
conjugated goat anti-chicken IgY (Life Technologies,
USA). The enzymatic color reaction was generated
using TMB substrate (Sigma, St.Louise, USA), stopped
with 0.5M H2SO4 and measured (OD450) as above.
Antibody endpoint titers
For determination of IgY endpoint titers two-fold serial
dilutions of chicken sera collected on day 35 (in range
from 10−3 to 10−6) were made and analyzed using the
ELISA protocol. Based on OD450 values the absorption
curves were made and the endpoint titers were determined
using Gen5 Data Analysis Software (BioTek Instruments,
Inc.).
Hemagglutination inhibition (HI)
HI tests were performed according to the OIE standard
procedures using the commercially available hemag-
glutinating antigen prepared from low pathogenic
H5N2 strain A/chicken/Belgium/150/1999 (DG Deventer,
Netherlands) with 96 % protein sequence similarity to the
vaccine antigen. For the HI test, serum to be tested was
serially two-fold diluted (1:8 to 1:512) in 25 μl of PBS in
V-bottom microtiter plates and an equal volume of HA
antigen containing 4 HA units was added. After incuba-
tion at room temperature (RT) for 25 min, 25 μl of a 1 %
suspension of hens’ red blood cells was added and incu-
bated for 25 min at RT. HI titers are shown as the recipro-
cal of the highest dilution of sera that completely inhibited
hemagglutination.
Cytokine production assay
Immunized and control mice were euthanized two weeks
after boost dose (day 63) and their spleens were harvested.
The spleen cell suspensions from the pooled two spleens
(from two randomly selected mice from the same group)
were washed in RPMI-1640 medium (Sigma, USA) and
treated for 5 min with the Lysis buffer (BD, Franklin
Fig. 1 Schedule of mice (a) and chickens (b) experiments
Table 1 Number of animals used in immunization experiments
DNA dose Number of animals per group
HAw/pCI K3/pCI GK/pCI pCI
Mice Experiment 1 20 μg 7 6 - 6
Experiment 2 10 μg - 6 7 -
50 μg - 6 6 2
Experiment 3 10 μg - 6 5 2
Experiment 4 20 μg - 6 6 2
Chickens Experiment 1 (Broilers) 60 μg 8 8 - 5
Experiment 2 (Layers) 60 μg - 6 6 2
Experiment 3 (Broilers) 60 μg - 10 9 4
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Lakes, USA) in order to clear red blood cells. To deter-
mine the amount of cytokines in culture supernatants,
splenocytes (2x106 per well) were incubated in 96-well
plates (Corning, Corning, USA) with complete RPMI-
1640 with 10 μg/ml of recombinant H5 HA protein puri-
fied from the baculovirus system (Oxford Expression
Technologies, England), 5 μg/ml Concavaline A (Con A)
or medium alone (see above). Cells were incubated for
72h (37 °C, 5 % CO2) and centrifuged (10 min, 1000 rpm,
4 °C). The level of cytokines was quantified in the col-
lected supernatants using Cytometric Bead Array Mouse
Th1/Th2/Th17 Cytokine Kit (BD, Franklin Lakes, USA)
according to the manufacturer’s instructions and the
FASCCalibur™ flow cytometer (BD, Franklin Lakes, USA).
Statistical analysis
Non-parametric tests, such as Kruskal-Wallis (for
comparison of multiple groups) or Wald-Wolfowitz,
Kolmogorov-Smirnov and Mann-Whitney U (for com-
parison of two groups) that are components of Statistica
12 (StatSoft, Poland) were used to evaluate the statistical
differences. The groups were considered significantly
different if at last one of the test was positive (p < 0.05).
Results
Verification of the HA expression cassettes in mammalian
cells
The HAw/pCI, K3/pCI and GK/pCI plasmids, containing
the variants of H5 HA from A/swan/Poland/305-135V08/
2006 (H5N1), were transiently transfected into the mam-
malian cells and the level of H5 HA protein produced by
the transfected cells was monitored (Fig. 2). The cells
transfected with GK/pCI usually produced about 15–30 %
more HA than the cells transfected with K3/pCI, while
the HA protein in cells transfected with HAw/pCI was
hardly detectable. These results indicated that enriching
nucleotide sequence encoding HA with GC in the third
positions of the codons improves the functionality of the
HA cassette in mice cells in comparison to the variant op-
timized for chicken codon bias.
Comparison of the effectiveness of HAw/pCI and K3/pCI
in two animal models
The effectiveness of two DNA vaccines, the wild type
(HAw/pCI) and the variant optimized for chicken codon
bias (K3/pCI), was compared in two model animals,
mice and chickens (broilers). The DNA doses and the
number of animals vaccinated with the compared vari-
ants is shown as Experiment 1 for either mice or chick-
ens in Table 1. The level of anti-H5 HA antibodies in
sera collected from the immunized mice and chickens
are shown in Fig. 3a and b, respectively. Both vaccine
plasmids stimulated anti-H5 HA humoral response with
apparently better parameters in the case of K3/pCI
groups, however the differences between K3/pCI and
HAw/pCI failed to pass the statistical significance test.
In both immunized organisms the geometric means
and/or medians of the K3/pCI groups were usually higher
than of the respective HAw/pCI groups, especially in sera
collected one week after the booster (day 56) for mice and
one and two weeks after the booster (days 28 and 35) for
chickens. Results of this experiment failed to indicate sig-
nificant differences between HAw/pCI and K3/pCI, how-
ever they might suggest that HAw/pCI is slightly inferior
in comparison to K3/pCI in both animal models.
Mice response to the optimized variants of DNA vaccine
The subsequent mice immunizations have been conducted
according to the same general scheme (Fig. 1a) in three in-
dependent experiments, labeled as Experiment 2, 3 and 4.
The results of one-dilution ELISA, detecting presence of
specific anti-H5 HA antibodies in mice sera are shown in
Fig. 4. The used doses of DNA and the number of animals
in each group are indicated in Table 1. The lowest dose of
the DNA (10 μg) was used two times, once in Experiment
2 and once in Experiment 3 but the statistically significant
differences between K3/pCI and GK/pCI groups were
observed only in Experiment 3, on days 49 and 56.
Each of the higher doses of DNA, 50 μg and 20 μg,
were tested only once, in Experiment 2 and 4, respect-
ively. The statistically significant differences between
Fig. 2 Expression of H5 HA in the C2C12 cell line (mouse myoblasts) transfected with the indicated plasmids: HAw/pCI, K3/pCI, GK/pCI and empty pCI
as a negative control. About 200 ng of recombinant H5 HA [A/Bar-Headed Goose/Qinghai/12/05 (H5N1)] was used as a positive control (HA). GAPDH
(Glyceraldehyde-3-phosphate dehydrogenase) represents the product of an intrinsic gene, was used as a loading control. Data are representative of at
least three independent experiments. L – Page Ruler™Prestaned Protein Ladder with the size of protein bands indicated
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the K3/pCI and GK/pCI groups were observed only in
case of 50μg dose on days 49 and 63 (Fig. 4).
The supernatants of liquid cultures of stimulated
splenocytes from the spleens isolated at the end of the
Experiment 4 (day 63) from two individuals per group
were used to measure the levels of interleukin 2 (IL-2),
interleukin 4 (IL-4), interleukin 6 (IL-6), interferon-γ
(IFN-γ), tumor necrosis factor (TNF), interleukin 17A
(IL-17A), and interleukin 10 (IL-10) in a single sample
(Fig. 5). The IL-4 and IL-17A were not detected in the
tested supernatants. No secretion of TNF, IL-6 and IL-2
or very low secretion IFN-γ was observed in the case of
activated splenocytes collected from the control group
vaccinated with the empty pCI vector (data not shown).
Interestingly, the level of IL-2 and IL-10 was several-
fold higher in the case of K3/pCI than GK/pCI, while
the levels of IFN-γ, TNF and IL-6 were higher in the
case of GK/pCI.
Fig. 3 Comparison of humoral responses in animals immunized with two variants of the DNA vaccine. The mice (a) and chickens (b) sera was tested for
the presence of the anti-H5 HA antibodies after immunization with the variant containing the wild type H5 HA (HAw/pCI) and the variant containing H5
HA optimized to the chicken codon bias (K3/pCI). The results of one-dilution ELISA for individuals, medians and the 10th and 90th percentiles are shown
for each group. The number of individuals was as indicated in Table 1, in Experiment 1 for mice and chickens, respectively. The values in the brackets are
the geometric means calculated for the K3/pCI and GK/pCI groups
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Fig. 4 (See legend on next page.)
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Chickens response to the optimized variants of DNA
vaccine
The optimized variants (K3/pCI and GK/pCI) of DNA
vaccine were used for immunization of layers and
broilers in two independent chicken experiments, labeled
as Experiment 2 and 3, respectively. The humoral re-
sponses were first evaluated by one-dilution ELISA using
the standard 200-fold dilutions of sera (Fig. 6a,b). The
medians were always higher in GK/pCI groups than in
the respective K3/pCI groups, however only in broilers
in sera collected on day 21 (two weeks after the first
dose) the differences passed the applied statistical sig-
nificance test (Fig. 6b).
Next, the endpoint titers of anti-H5 HA in the sera
collected two weeks after the booster (on day 35) were
assayed and, in order to facilitate the interpretation of
data, they were arbitrarily divided into four categories:
high (>105), medium (104-105), low (103-104) and very
low (<103) (Fig. 6c). In layers, none of the probes from
the K3/pCI group reached the end-point titer above
105 and 33 % of probes did not exceed the titer above
103, in contrast to the 33 and 17 % of such probes, re-
spectively, in the case of GK/pCI group. The highest
titer of layers’ sera from K3/pCI and GK/pCI group
was 7 × 104 and 4 × 105, respectively. The endpoint ti-
ters of the broilers’ sera indicated less variability within
the groups and the highest titers were more similar
(both about 2 × 105). In broilers, 40 % of the probes
from the K3/pCI group had titers above 105 and all of
them were above 103, while all sera from the GK/pCI
group had titers above 104, including 33 % with the
titer above 105.
The results of hemagglutination inhibitions (HI) test
seem to confirm a slightly better performance of the
GK/pCI vaccine over the K3/pCI vaccine in both
chicken experiments, however the differences are not
statistically significant (Fig. 6d).
Discussion
DNA vaccines containing the optimized variants of H5
HA gene induced strong and specific immune responses
in mice and chickens. In both animal models the slight
superiority of GK/pCI over K3/pCI was observed. The
observed differences were frequently statistically signifi-
cant. Changes within GK did not regard the codon usage
preference in any particular organism but the key was
maximization of the GC content at the third coding pos-
ition of HA (43, 65 and 99.8 % in HAw/pCI, K3/pCI and
GK/pCI, respectively). This study was inspired by the
previous reports indicating that an increased GC content
provides better mRNA stability, processing and nucleo-
cytoplasmic transport [18, 20]. In fact, our results can be
explained and are in full agreement with the above lit-
erature data. We started with verification of the modified
cassettes by monitoring of the level of HA protein pro-
duced in mouse muscle cells (C2C12) transfected with
K3/pCI and GK/pCI. Indeed, about 15–30 % higher level
of HA protein production was observed in cells trans-
fected with GK/pCI than with K3/pCI, which corresponds
well with apparently higher immune responses to GK/pCI
than to K3/pCI in the immunized animals. The correl-
ation between in vitro expression in transfected cells and
immunogenicity of DNA vaccine was also observed by
others [24, 25].
Little is known about the timing of cytokine produc-
tion after immunization. We investigated the profiles of
cytokines in the supernatants from the cultured, stimu-
lated with H5 HA for 72h, mice splenocytes that were
isolated from the spleens of the immunized animals. In
the supernatants we confirmed the presence of five of
(See figure on previous page.)
Fig. 4 Comparison of humoral responses in mice immunized with two optimized variants of DNA vaccine. The presence of anti H5 HA antibodies
was monitored in sera collected from the animals on the indicated days in three independent experiments, Experiments 2, 3 and 4 (see also Table 1).
The results for individuals, medians and the 10th and 90th percentiles are shown for each group. Statistically significant differences between groups
K3/pCI and GK/pCI (p < 0.05) are marked by asterisks. The arrows show from which individuals the spleens have been harvested. The values in
the brackets are the geometric means calculated for the K3/pCI and GK/pCI groups
Fig. 5 Levels of selected cytokines produced by H5 HA-stimulated splenocytes. The assay was performed with the splenocytes isolated from two
pulled down spleens (from two individuals from the same group, indicated by arrows in Fig. 4) collected at the end of experiment (day 63)
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seven tested cytokines. The levels of IFN-γ, TNF and
IL-6 were higher in the group immunized with GK/pCI
than with K3/pCI. This result suggests that codon
optimization affects both branches of immune re-
sponses, humoral (IL-6) and cellular (IFN-γ, TNF) what
was previously reported in studies with HIV and HPV
DNA vaccine [26, 27]. The lower levels of IL-2 and IL-10
in GK/pCI than K3/pCI group is unclear and need further
investigation. The lower level of IL-2 was also observed by
Tenbusch et al. in stimulated CD4+ from mice immunized
with DNA vaccine containing the optimized sequence
for the HA from H1N1 [9]. We did not detect IL-4 nor
IL-17A. The lack of IL-17A might be explained by the
high concentration of IFN-γ negatively regulating the
induction of Th17 cells [28]. The lack of IL-4 might be
explained by the conditions of the assay and splenocytes
cultivation (and induction) which were optimal for IFN-γ
but not IL-4 detection due to the short half-life of the let-
ter [29]. Additional analysis of mice sera (data not shown)
indicated that although the level of IgG2a (one of two
major isotypes of antibodies) was rather similar in both
groups, the level of IgG1 was slightly higher in GK/pCI
than in K3/pCI. This result might suggest that the eleva-
tion of immune response in GK/pCI group concerned
mostly the elevation of Th2 type, however these aspects of
the response to the vaccine variants require more studies.
Better efficacy of GK/pCI than K3/pCI observed in
chickens is in contrast with the results by Rao et al. [30]
who reported that in chicken genome the GC content at
the third coding position is negatively correlated with
the expression level and that it is not correlated with the
maximum expression level. Based on their own analysis,
the authors stated that the GC content in genes (general,
not only in the third codon positions) could explain only
Fig. 6 Comparison of humoral responses in sera of chickens immunized with two optimized variants of DNA vaccine. The results for individuals,
medians and the 10th and 90th percentiles are shown for K3/pCI and GK/pCI groups of layers (a) and broilers (b). The percentage distribution of
IgY endpoint titers into four categories within the groups and the HI titers are presented in panels (c) and (d), respectively. The number of individuals
was as indicated in Table 1, in Experiment 2 and Experiment 3 for layers and broilers, respectively. The values in the brackets are the geometric means
calculated for the K3/pCI and GK/pCI groups
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approximately 10 % of the variation in gene expres-
sion. According to Kudla at al. [20] the efficient tran-
scription or mRNA processing is responsible for the
high expression of GC-rich gene, while other re-
searchers (for example [31, 32]) assumed that the in-
creased expression of codon–optimized genes was
caused by the more efficient translational mechan-
ism. The high effectiveness of the variant with nearly
100 % codons with GC at the third position in both
model animals (regardless of the codon usage prefer-
ences) suggests that the first hypothesis might be
correct.
Interestingly, the immunization was generally more
effective in broilers than in layers. The results of ELISA
test, as well as of HI test were less variable within the
broiler groups (70–88 % positives). Immunization of
the layers type chickens gave slightly lower and more
variable antibody levels and slightly worse results in the
HI test (Fig. 5c). On average, the endpoint titers were
lower in layers than in broilers, particularly in K3/pCI
groups. Many factors can disturb the effectiveness of
immunization and the chickens might respond in a very
individual way, as observed by others, too [15]. DNA
uptake by the target cells, preceded by penetration of
sufficient area of tissue after injection seems to be cru-
cial. It is worth to emphasize that the dose chosen for
chickens’ immunization was suboptimal for better
visualization of the expected differences in immune
response. Differences in the strength and dynamic of
broilers’ and layers’ responses can be linked to the
different genetic background of two used chicken types,
differences in their metabolism, growth and development
which are results of intensive genetic selection [33].
Chickens are not so popular animal model as mice in im-
munological studies, still considerable number of publica-
tions about chicken immunization with DNA vaccine,
especially with avian influenza antigens are available [7].
Most of such experiments were performed with specific
pathogen free White Leghorn chickens. In this study we
used birds, which are popularly used in Poland for the
commercial purposes: the broiler line Ross 308 and the
layer line Rosa 1 (a hybrid of Rhode Island and Sussex)
and kept them in standard commercial conditions, which
allow us to observe natural reactions to the immuniza-
tions. Moreover, to our knowledge this is the first report
on comparison of the layers’ and the broilers’ humoral
responses to the DNA vaccine. Some papers comparing
immunological responses of broiler and layer types are
available [34–36], however in these experiments con-
ventional vaccines against Salmonella sp. were used, or
synthetic peptide antigen, not originated from any
poultry disease. Similarly to our results, differences in
responses between broilers and layers have been previ-
ously reported.
Conclusion
In summary, our results strongly suggest that the enhance-
ment of GC content in the third positions of the codons is
a promising strategy for development of DNA vaccine that
could be highly effective in a broad range of target species,
such as birds and mammals, including humans.
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